Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.

Ado-Trastuzumab Emtansine / therapeutic use Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Body Mass Index Breast Neoplasms / drug therapy Disease Progression Female Humans Middle Aged Obesity / complications Overweight / complications Progression-Free Survival Receptor, ErbB-2 / genetics
HER2-positive metastatic breast cancer body mass index pertuzumab trastuzumab emtansine

Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 11 2019
accepted: 04 12 2019
pubmed: 17 1 2020
medline: 9 3 2021
entrez: 17 1 2020
Statut: ppublish

Résumé

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.

Identifiants

DOI: 10.1002/jcp.29445 PMID: 31943171
pubmed: 31943171
doi: 10.1002/jcp.29445
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents, Immunological 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
pertuzumab K16AIQ8CTM
Ado-Trastuzumab Emtansine SE2KH7T06F

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

7900-7910

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Baselga, J., Cortés, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., … Pedrini, L. CLEOPATRA Study Group (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366, 109-119. https://doi.org/10.1056/NEJMoa1113216
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014). Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5·24 million UK adults. Lancet, 384, 755-765. https://doi.org/10.1016/S0140-6736(14)60892-8
Cleveland, R. J., Eng, S. M., Abrahamson, P. E., Britton, J. A., Teitelbaum, S. L., Neugut, A. I., & Gammon, M. D. (2007). Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 16, 1803-1811. https://doi.org/10.1158/1055-9965.EPI-06-0889
Conte, P. F., Guarneri, V., Bruzzi, P., Prochilo, T., Salvadori, B., Bolognesi, A., … Venturini, M. Gruppo Oncologico Nord Ovest (2004). Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: Results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer, 101, 704-712. https://doi.org/10.1002/cncr.20400
De Censi, A., & Gennari, A. (2011). Insulin breast cancer connection: Confirmatory data set the stage for better care. Journal of Clinical Oncology, 29, 7-10. https://doi.org/10.1200/JCO.2010.32.3022
Denney-Wilson, E., Hardy, L. L., Dobbins, T., Okely, A. D., & Baur, L. A. (2008). Body mass index, waist circumference, and chronic disease risk factors in Australian adolescents. Archives of Pediatrics and Adolescent Medicine, 162, 566-573. https://doi.org/10.1001/archpedi.162.6.566
Fiorio, E., Mercanti, A., Terrasi, M., Micciolo, R., Remo, A., Auriemma, A., & Surmacz, E. (2008). Leptin/HER2 crosstalk in breast cancer: In vitro study and preliminary in vivo analysis. BMC Cancer, 8, 305. https://doi.org/10.1186/1471-2407-8-305
Flegal, K. M., Kit, B. K., & Graubard, B. I. (2014). Body mass index categories in observational studies of weight and risk of death. American Journal of Epidemiology, 180, 288-296. https://doi.org/10.1093/aje/kwu111
Gennari, A., Amadori, D., De Lena, M., Nanni, O., Bruzzi, P., Lorusso, V., & Conte, P. F. (2006). Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. Journal of Clinical Oncology, 24, 3912-3918. https://doi.org/10.1200/JCO.2006.06.1812
Gennari, A., Nanni, O., Puntoni, M., DeCensi, A., Scarpi, E., Conte, P., & Bruzzi, P. (2013). Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. Cancer Epidemiology, Biomarkers & Prevention, 22, 1862-1867. https://doi.org/10.1158/1055-9965.EPI-13-0595
Jung, S. Y., Rosenzweig, M., Sereika, S. M., Linkov, F., Brufsky, A., & Weissfeld, J. L. (2012). Factors associated with mortality after breast cancer metastasis. Cancer Causes & Control, 23, 103-112. https://doi.org/10.1007/s10552-011-9859-8
Kearns, K., Dee, A., Fitzgerald, A. P., Doherty, E., & Perry, I. J. (2014). Chronic disease burden associated with overweight and obesity in Ireland: The effects of a small BMI reduction at population level. BMC Public Health, 14, 143. https://doi.org/10.1186/1471-2458-14-143
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001). Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism, 280, E745-E75. https://doi.org/10.1152/ajpendo.2001.280.5.E745
Khan, S. S., Ning, H., Wilkins, J. T., Allen, N., Carnethon, M., Berry, J. D., & Lloyd-Jones, D. M. (2018). Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiology, 3, 280-287. https://doi.org/10.1001/jamacardio.2018.0022
Kroenke, C. H., Chen, W. Y., Rosner, B., & Holmes, M. D. (2005). Weight, weight gain, and survival after breast cancer diagnosis. Journal of Clinical Oncology, 23, 1370-1378. https://ascopubs.org/doi/10.1200/JCO.2005.01.079
Lagathu, C., Bastard, J. P., Auclair, M., Maachi, M., Capeau, J., & Caron, M. (2003). Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochemical and Biophysical Research Communications, 311, 372-379. https://doi.org/10.1016/j.bbrc.2003.10.013
Martel, S., Poletto, E., Ferreira, A. R., Lambertini, M., Sottotetti, F., Bertolini, I., & Puglisi, F. (2018). Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast (Edinburgh, Scotland), 37, 142-147. https://doi.org/10.1016/j.breast.2017.11.004
Morimoto, L., White, E., Chen, Z., Chlebowski, R., Hays, J., Kuller, L., & McTiernan, A. (2002). Obesity, body size, and risk of postmenopausal breast cancer: The women's health initiative (United States). Cancer Causes & Control, 13, 741-751. www.jstor.org/stable/3553553
Parolin, V., Fiorio, E., Mercanti, A., Riolfi, M., Cetto, G. L., Surmacz, E., & Molino, A. (2010). Impact of BMI on clinical outcome of HER2-positive breast cancer. Journal of Clinical Oncology, 28(Suppl. 15), 1130. https://doi.org/10.1200/jco.2010.28.15_suppl.1130. abstract 1130.
Passardi, A., Massa, I., Zoli, W., Gianni, L., Milandri, C., Zumaglini, F., & Amadori, D. (2006). Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: A translational research experience. BMC Cancer, 6, 76. https://doi.org/10.1186/1471-2407-6-76
Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017). Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: A Cancer Journal for Clinicians, 67, 378-397. https://doi.org/10.3322/caac.21405
Picon-Ruiz, M., Pan, C., Drews-Elger, K., Jang, K., Besser, A. H., Zhao, D., & Slingerland, J. M. (2016). Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/Sox2/miR-302b mediated malignant progression. Cancer Research, 76, 491-504. https://doi.org/10.1158/0008-5472.CAN-15-0927
Pizzuti, L., Marchetti, P., Natoli, C., Gamucci, T., Santini, D., Scinto, A. F., & Vici, P. (2017). Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. Scientific Reports, 7, 10597. https://doi.org/10.1038/s41598-017-10061-2
Pizzuti, L., Sergi, D., Sperduti, I., Lauro, L. D., Mazzotta, M., Botti, C., & Vici, P. (2018). Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biology & Therapy, 19, 328-334. https://doi.org/10.1080/15384047.2017.1416938
Purohit, A., & Reed, M. J. (2002). Regulation of estrogen synthesis in postmenopausal women. Steroids, 67, 979-983. https://doi.org/10.1016/S0039-128X(02)00046-6
Rose, D. P., & Vona-Davis, L. (2009). Influence of obesity on breast cancer receptor status and prognosis. Expert Review of Anticancer Therapy, 9, 1091-1101. https://doi.org/10.1586/era.09.71
Saxena, N. K., Taliaferro-Smith, L., Knight, B. B., Merlin, D., Anania, F. A., O'Regan, R. M., & Sharma, D. (2008). Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Research, 68, 9712-9722. https://doi.org/10.1158/0008-5472.CAN-08-1952
Smith, K. B., & Smith, M. S. (2016). Obesity statistics. Primary Care: Clinics in Office Practice, 43, 121-135. https://doi.org/10.1016/j.pop.2015.10.001
Strulov Shachar, S., & Williams, G. R. (2017). The obesity paradox in cancer-moving beyond BMI. Cancer Epidemiology, Biomarkers & Prevention, 26, 13-16. https://doi.org/10.1158/1055-9965.EPI-16-0439
Tornatore, L., Thotakura, A. K., Bennett, J., Moretti, M., & Franzoso, G. (2012). The nuclear factor kappa B signaling pathway: Integrating metabolism with inflammation. Trends in Cell Biology, 22, 557-566. https://doi.org/10.1016/j.tcb.2012.08.001
van Kruijsdijk, R. C., van der Wall, E., & Visseren, F. L. (2009). Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiology, Biomarkers & Prevention, 18, 2569-2578. https://doi.org/10.1158/1055-9965.EPI-09-0372
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., … Lu, M. W. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367, 1783-1791. https://doi.org/10.1056/NEJMoa1209124
von Drygalski, A., Tran, T. B., Messer, K., Pu, M., Corringham, S., Nelson, C., & Ball, E. D. (2011). Obesity is an independent predictor of poor survival in metastatic breast cancer: Retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. International Journal of Breast Cancer, 2011, 523276-8. https://doi.org/10.4061/2011/523276
Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., … Brodowicz, T. TURANDOT investigators (2016). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): Primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology, 17, 1230-1239. https://doi.org/10.1016/S1470-2045(16)30154-1

Auteurs

Eriseld Krasniqi (E)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Laura Pizzuti (L)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giacomo Barchiesi (G)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Domenico Sergi (D)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Silvia Carpano (S)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Claudio Botti (C)

Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Ramy Kayal (R)

Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giuseppe Sanguineti (G)

Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Paolo Marchetti (P)

Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" University of Rome, Rome, Italy.

Andrea Botticelli (A)

Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.

Daniele Marinelli (D)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" University of Rome, Rome, Italy.

Teresa Gamucci (T)

Medical Oncology, Sandro Pertini Hospital, Rome, Italy.

Clara Natoli (C)

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.

Antonino Grassadonia (A)

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.

Nicola Tinari (N)

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, Chieti, Italy.

Silverio Tomao (S)

Department of Radiological, Oncological and Anatomo-Pathological Sciences, Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.

Giuseppe Tonini (G)

Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.

Daniele Santini (D)

Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.

Aandrea Michelotti (A)

Dipartimento di Oncologia, Dei Trapianti e Delle Nuove Tecnologie, UO Oncologia Medica I, S. Chiara Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

Lucia Mentuccia (L)

Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.

Aangela Vaccaro (A)

Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.

Emanuela Magnolfi (E)

Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.

Alain Gelibter (A)

Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.

Valentina Magri (V)

Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.

Enrico Cortesi (E)

Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.

Loretta D'Onofrio (L)

Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.

Alessandra Cassano (A)

Department of Medical Oncology, Policlinico Universitario "A. Gemelli", Rome, Italy.

Marina Cazzaniga (M)

Research Unit Phase I Trials and Oncology Unit, ASST Monza, Monza, Italy.

Luca Moscetti (L)

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.

Agnese Fabbri (A)

Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.

Angelo Fedele Scinto (AF)

Medical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.

Domenico Corsi (D)

Medical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.

Luisa Carbognin (L)

University of Verona, Verona, Italy.
Division of Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Emilio Bria (E)

University of Verona, Verona, Italy.
Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Roma, Italy.

Nicla La Verde (N)

Oncology Unit, ASST Fatebenefratelli Sacco Presidio Ospedaliero Fatebenefratelli, Milano, Italy.

Carlo Garufi (C)

Medical Oncology, "Santo Spirito" Hospital, Pescara, Italy.

Pia Di Stefano (P)

Medical Oncology, "Santo Spirito" Hospital, Pescara, Italy.

Rossana Mirabelli (R)

Department of Hematology & Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.

Enzo Veltri (E)

Oncology Unit, S. Maria Goretti Hospital, Latina, Italy.

Ida Paris (I)

Division of Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Francesco Giotta (F)

Department of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.

Vito Lorusso (V)

Department of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.

Elisa Landucci (E)

Dipartimento di Oncologia, Dei Trapianti e Delle Nuove Tecnologie, UO Oncologia Medica I, S. Chiara Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

Corrado Ficorella (C)

Department of Biotechnological and Applied Clinical Sciences, Medical Oncology, University of L'Aquila, L'Aquila, Italy.

Mario Roselli (M)

Department of Systems Medicine, Medical Oncology, University of Rome "Tor Vergata", Rome, Italy.

Vincenzo Adamo (V)

Department of Human Pathology, Medical Oncology Unit A.O. Papardo, University of Messina, Messina, Italy.

Giuseppina Ricciardi (G)

Department of Human Pathology, Medical Oncology Unit A.O. Papardo, University of Messina, Messina, Italy.

Antonio Russo (A)

Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.

Maria Rosaria Valerio (MR)

Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.

Rossana Berardi (R)

Oncology Clinic, Università Politecnica delle Marche, Ancona, Italy.

Mirco Pistelli (M)

Oncology Clinic, Università Politecnica delle Marche, Ancona, Italy.

Katia Cannita (K)

Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.

Claudio Zamagni (C)

Medical Oncology Unit, Addarii Institute of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.

Ornella Garrone (O)

Medical Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, Cuneo, Italy.

Editta Baldini (E)

Department of Oncology, San Luca Hospital, Lucca, Italy.

Lorenzo Livi (L)

Department of Clinical and Experimental Biomedical Sciences "Mario Serio," Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Icro Meattini (I)

Department of Clinical and Experimental Biomedical Sciences "Mario Serio," Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Pietro Del Medico (P)

Division of Medical Oncology, Reggio Calabria General Hospital, Reggio Calabria, Italy.

Daniele Generali (D)

Breast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy.

Ruggero De Maria (R)

Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy.

Emanuela Risi (E)

Department of "Sandro Pitigliani" Medical Oncology, Santo Stefano Hospital, Prato, Italy.

Gennaro Ciliberto (G)

Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Alice Villa (A)

Endocrinology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma - Università Cattolica del Sacro Cuore, Rome, Italy.

Isabella Sperduti (I)

Department of Bio-Statistics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Marco Mazzotta (M)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" University of Rome, Rome, Italy.

Maddalena Barba (M)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
ORCID: 0000-0001-9050-2917

Antonio Giordano (A)

Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania.
ORCID: 0000-0003-4353-5390

Patrizia Vici (P)

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
ORCID: 0000-0001-7528-9783

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Trastuzumab › Ado-trastuzumab emtansine › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Biométrie › Anthropométrie › Indice de masse corporelle › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Apparence corporelle › Surpoids › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans progression › Impact of BMI on HER2+ metastatic breast...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Impact of BMI on HER2+ metastatic breast...